The European Association of Urology (EAU) 2016 Congress will be held from 11 to 15 of March in Munich, Germany. Asieris pharmaceuticals’ ongoing project “China Phase II Clinical Trial of APL-1202, an Oral metaP2 Inhibitor, in Patients with High-Risk NMIBC and Relapsed after Intravesical Therapies” has attracted the attention of the organizing committee and has been invited to attend the congress and present the interim results.
